Plant vaccines: An immunological perspective

Current Topics in Microbiology and Immunology

Volumn 332, Issue , 2010, Pages 1-11

  Hooper, D C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLANT VACCINE; UNCLASSIFIED DRUG; VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; BACTERIUM; BIOENGINEERING; DRUG EFFICACY; DRUG SAFETY; EXPRESSION VECTOR; HETEROLOGOUS EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; NONHUMAN; PLANT VIRUS; PRIORITY JOURNAL; REVIEW; TRANSGENIC PLANT; VACCINE PRODUCTION; BIOSYNTHESIS; BIOTECHNOLOGY; IMMUNOLOGY; METABOLISM; METHODOLOGY; PLANT;

BIOTECHNOLOGY; HUMANS; PLANTS; VACCINES;

EID: 67849095741     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-70868-1_1     Document Type: Review

References (35)

1. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE (2000) Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. Curr Pharm Des 6:261-276
2. CDC (2002) General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Mort Morbid Wkly Rep 51(RR02):1-36
3. Choe NW, Estes MK, Langridge WH (2006) Synthesis of a ricin toxin B subunit-rotavirus VP7 fusion protein in potato. Mol Biotechnol 32:117-128
4. Choi NW, Esters MK, Langridge WH (2006) Ricin Toxin B subunit enhancement of rotavirus NSP4 immunogenicity in mice. Viral Immunol 19:54-63
5. Cohen-Kaminsky S, Jambou F (2005) Prospects for a T-cell receptor vaccination against myasthenia gravis. Expert Rev Vaccines 4:473-492
6. Cui Z, Qiu F (2006) Synthetic double-stranded RNA poly (I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol Immunother 55:1267-1279
7. Diebold SS, Plank C, Cotton M, Wagner E, Zenke M (2002) Mannose receptor-mediated gene delivery into antigen presenting dendritic cells. Somat Cell Mol Genet 27:65-74
8. Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI, Dalgleish AG (2002) Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 168:4914-4919
9. Faria AM, Weiner HL (2005) Oral tolerance. Immunol Rev 206:232-259
10. Fujihashi K, Koga T, van Ginkel FW, Hagiware Y, McGhee JR (2002) A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20:2431-2438
11. Gleba Y, Klimyuk V, Marillonnet S (2005) Magnification-a new platform for expressing recombinant vaccines in plants. Vaccine 23:2042-2048
12. Gustafson GL, Rhodes MJ (1992) Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res Immunol 143:483-488
13. Hanlon CA, DeMattos CA, DeMattos CC, Niezgoda M, Hooper DC, Koprowski H, Notkins A, Rupprecht CE (2001) Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis. Vaccine 19:3834-3842
14. Helm RM, Furuta GT, Stanley JS, Ye J, Cockrell G, Connaughton C, Simpson P, Bannon GA, Burks AW (2002) A neonatal swine model for peanut allergy. J Allergy Clin Immunol 109:136-142
15. Jalava K, Eko FO, Riedmann E, Lubitz W (2003) Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Rev Vaccines 2:45-51
16. Jenner E (1798) An inquiry into the causes and effects of the variolae vaccine. London: printed for the author by Sampson Law
17. Keller MA, Stiehm ER (2000) Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 13:602-614
18. Ko K, Tekoah Y, Rudd PM, Harvey DJ, Dwek RA, Spitsin S, Hanlon CA, Rupprecht C, Dietzschold B, Golovkin M, Koprowski H (2003) Function and glycosylation of plant-derived antiviral monoclonal antibody. Proc Natl Acad Sci U S A 100:8013-8018
19. Ko K, Steplewski Z, Glogowska M, Koprowski H (2005) Inhibition of tumor growth by plantderived mAb. Proc Natl Acad Sci U S A 102:7026-7030
20. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709-760
21. Kumpel BM (2002) On the mechanism of tolerance to the Rh D antigen mediated by passive anti-D (Rh D prophylaxis). Immunol Lett 82:67-73
22. Lenarczyk A, Le TT, Drane D, Malliaros J, Pearse M, Hamilton R, Cox J, Luft T, Gardner J, Suhrbier A (2004) ISCOM based vaccines for cancer immunotherapy. Vaccine 22:963-974
23. Li ZG, Mu R, Dai ZP, Gao XM (2005) T cell vaccination in systemic lupus erythematosus with autologous activated T cells. Lupus 14:884-889
24. Lyche N (2005) Targeted vaccine adjuvants based on modified cholera toxin. Curr Mol Med 5:591-597
25. Pasteur L (2002) Summary report of the experiments conducted at Pouilly-le-Fort Near Melun, on the anthrax vaccination. Classics of Biology and Medicine. Yale J Biol Med 75:59-62
26. Ramon G, Zoeller C (1927) Lanatoxine tétanique et limmunisation active de lhomme vis-à-vis du tétanos. Ann Inst Pasteur 41:803-833
27. Robinson JH, Delvig AA (2002) Diversity in MHC class II antigen presentation. Immunology 105:252-262
28. Sawyer LA (2000) Antibodies for the prevention and treatment of viral diseases. Antiviral Res 47:57-77
29. Schijns VE (2001) Induction and direction of immune responses by vaccine adjuvants. Crit Rev Immunol 21:75-85
30. Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425(6957):516-521
31. Vandenbark AA, Morgan E, Bartholomew R, Bourdette D, Whitham R, Carlo D, Gold D, Hashim G, Offner H (2001) TCR peptide therapy in human autoimmune diseases. Neurochem Res 26:713-730
32. Verch T, Yusibov V, Koprowski H (1998) Expression and assembly of a full-length monoclonal antibody in plants using a plant virus vector. J Immunol Methods 220:69-75
33. Vichier-Guerre S, Lo-Man R, BenMohamed L, Deriaud E, Kovats S, Leclerc C, Bay S (2003) Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anticancer vaccine for human use. J Pept Res 62:117-124
34. Weinstein PD, Cebra JJ (1991) The preference for switching to IgA expression by Peyers patch germinal center B cells is likely due to the intrinsic influence of their microenvironment. J Immunol 147:4126-4135
35. Yusibov V, Hooper DC, Spitsin SV, Fleysh N, Kean RB, Mikheeva T, Deka D, Karasev A, Cox S, Randall J, Koprowski H (2002) Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 20:3155-3164